A significant advancement in tumor immunotherapy is the development and clinical use of immune checkpoint inhibitors (ICIs), particularly inhibitors such as cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), programmed death 1 (PD-1), and PD ligand 1 (PD-L1). The gene discussed is CD274; the disease is neoplasm.